Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 6NIH 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 7Dermatologic 7Lymphoid 6Genitourinary 6Gynecologic 5Head & Neck 3Breast 3Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1CNS 1

Conditions

Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × aldesleukin × Other solid neoplasm × Clear all
NCT04862767 2024-01-31

TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

Autotelicbio

Phase 1 Completed
9 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡